Contact us
We welcome inquiries from patients and caregivers, healthcare professionals, members of the media, investors, potential partners and others interested in Vaderis and our work.
Please complete the form below and select the topic that best describes your inquiry. This will help us direct your message to the appropriate member of our team.
Information submitted through the form will be handled in accordance with the Vaderis Privacy Statement.
Clinical Study Information
Interested in learning more about the HEROIC Phase 3 clinical study?
The HEROIC Phase 3 clinical study is evaluating engasertib, an investigational oral therapy, in adults with moderate to severe hereditary hemorrhagic telangiectasia (HHT).
Learn more about the HEROIC study here.
For Patients and Caregivers
We appreciate hearing from patients, caregivers and members of the HHT community.
Vaderis cannot provide individual medical advice or make recommendations regarding medical care or treatment. Patients and caregivers should speak with a qualified healthcare professional about questions related to their health, diagnosis or treatment.
For information about Vaderis’ policy regarding access to investigational medicines outside of clinical studies view our Expanded Access Policy here.